


BEACON


Building Effective Amyloidosis Care Networks



ATTR-CM: Management and Treatment

Patient and Therapy Selection¹


Patient Selection and Choice of ATTR-CM Disease-Modifying Therapies



6MWD, 6-minute walk distance; ATTR-CM, transthyretin cardiac amyloidosis; ATTRv-CM, variant transthyretin amyloid cardiomyopathy; ATTRwt-CM, wild-type transthyretin cardiac amyloidosis; eGFR, estimated glomerular filtration rate; HF, heart failure; MRA, mineralocorticoid antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SGLT2, sodium-glucose cotransporter-2; TTR, transthyretin

BEACON

Building Effective **Amyloidosis** Care Networks



ATTR-CM: Management and Treatment

Emerging Therapies


Following are Phase 3 trials for ATTR-CM

Therapy	Trial	Mechanism	Route	N
Eplontersen	CARDIO-TTRansform NCT04136171	Silencer (ASO)	SQ Q1 month	1,438
Nex-z (NTLA-2001)	MAGNITUDE* NCT06128629	Gene editing (CRISPR)	IV once	765
ALXN2220 (NI006)	DepleTTR-CM NCT06183931	Anti-amyloid antibody	IV monthly	1,158
NNC6019 (PRX004)	CleopaTTRa NCT07207811	Anti-amyloid antibody	IV monthly	1,280
Nucresiran	TRITON-CM NCT07052903	Silencer	SQ Q6 months	1,250

Current as of November 18, 2025; *paused October, 2025 due to liver toxicity


BEACON

Building Effective Amyloidosis Care Networks



ATTR-CM: Management and Treatment

Patient Monitoring, Longitudinal Care, and Follow-Up^{1,2}




Educating Patients About Monitoring and Follow-Up³

Patients must understand the importance of monitoring and follow-up. At minimum, provide the following information:

- **Why monitoring matters.** To identify new symptoms or disease progression, to preserve quality of life, and prevent hospitalizations
- **What to expect.** The symptoms that will be assessed, labs that will be performed, and interval for imaging and other tests
- **How to monitor at home.** The vitals that a patient must monitor daily (weight, BP, HR), keeping a symptom diary, list of questions to ask at next clinic visit
- **When to call the health team.** Which new or worsening symptoms should prompt a call, specialty to contact, method of contact (patient portal, phone, etc.)

BEACON

Building Effective **Amyloidosis** Care Networks



ATTR-CM: Management and Treatment

Key Takeaways

- Multiple TTR protein production blockers and protein stabilizers have been approved by the FDA to treat ATTR-CM
- Several therapies are in clinical trials, including TTR depleters and CRISPR-based protein suppression
- In addition to disease-modifying therapies, symptom management is also essential
 - Follow guideline-directed care for heart failure in ATTR-CM
 - Use a multidisciplinary team
- Serial monitoring is required—biomarkers, functional tests, use of diuretics
- Empower patients to participate in their care

References

1. Writing Committee, Kittleson MM, Ambardekar AV, et al. [J Am Coll Cardiol. Published online October 31, 2025.](#)
2. Patel RK, et al. [JAMA Cardiol. 2024;9\(4\):367-376.](#)
3. Writing Committee, Kittleson MM, Ruberg FL, et al. [J Am Coll Cardiol. 2023;81\(11\):1076-1126. doi:10.1016/j.jacc.2022.11.022](#)